Generated by AI
Absci Corporation is a clinical-stage biopharmaceutical company focused on discovering and designing protein-based therapeutics using generative artificial intelligence and synthetic biology. Absci integrates AI-driven modeling with high-throughput wet lab capabilities to create antibody and other biologic candidates for complex disease areas. Its current pipeline spans programs in immunology, oncology, inflammatory disease, and dermatology, reflecting a platform approach to drug creation rather than a single-product model. The company also collaborates with pharmaceutical and biotechnology partners to support therapeutic discovery and development efforts. Headquartered in Vancouver, Washington, Absci plays a role in the growing market for AI-enabled drug discovery, where data science and biological engineering are combined to improve how new medicines are identified and optimized.
Website18105 SE Mill Plain Boulevard
Vancouver, WA, 98683
United States
The latest articles about ABSI.
Summary of Nov 16's posts. Generated by AI.
Summary of Oct 29's posts. Generated by AI.
Summary of Jan 8's posts. Generated by AI.
Summary of Oct 29's posts. Generated by AI.
Investors talking about ABSI also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.